Biogen(NASDAQ:BIIB) is the latest biotech stock to light up investment news after a bombshell announcement. One of the company's drugs received unexpected clearance from the FDA, opening the door to monstrous profits in the near future. Shares leaped more than 60% to $407 on the news. That's a hefty price tag that might be prohibitive for some investors, but there's a simple strategy that you can use that makes Biogen affordable for anyone.

A 61% year-to-date return is spectacular, but it might surprise you to see that these gains were achieved in a matter of days.

^NDX data by YCharts

Prior to the recent jump, the stock was fairly flat for 18 months. It bounced around a good amount between $250 and $350 per share, but it never moved decisively in either direction.

On June 7, the company announced that it had received FDA clearance for accelerated approval of its drug ADUHELM. ADUHELM treats Alzheimer's disease by reducing plaque buildup in the brain, and it could be the first genuinely effective pharmaceutical treatment to combat the debilitating illness.

More in category

Square to buy Australia’s Afterpay in $29 billion deal
August 01, 2021MarketWatch
Square to buy Australia’s Afterpay in $29 billion deal
My brother and I each invested $10K in a home 10 years ago. Now I want out. How much do I get back?
August 01, 2021MarketWatch
My brother and I each invested $10K in a home 10 years ago. Now I want out. How much do I get back?
Alibaba stock has taken a hit from China crackdown, but its earnings could be a different story
July 30, 2021MarketWatch
Alibaba stock has taken a hit from China crackdown, but its earnings could be a different story
Opinion: As Congress clashes over borrowing and debt, gold is likely to beat stocks
July 30, 2021MarketWatch
Opinion: As Congress clashes over borrowing and debt, gold is likely to beat stocks
Opinion: Investors are accused of being obsessed with short-term results. The popularity of growth stocks proves otherwise
July 30, 2021MarketWatch
Opinion: Investors are accused of being obsessed with short-term results. The popularity of growth stocks proves otherwise
Home prices could cool when the Fed tapers its bond-buying program. But a crisis? Unlikely.
July 31, 2021MarketWatch
Home prices could cool when the Fed tapers its bond-buying program. But a crisis? Unlikely.
Opinion: Here’s how the 6 Big Tech stocks now rank, from worst to first
July 30, 2021MarketWatch
Opinion: Here’s how the 6 Big Tech stocks now rank, from worst to first
My parents had drug and alcohol addiction. My ailing mother got sober, but now overspends and gambles. She wants to move in. What do I owe her?
July 29, 2021MarketWatch
My parents had drug and alcohol addiction. My ailing mother got sober, but now overspends and gambles. She wants to move in. What do I owe her?
COVID-19 vaccine mandates gain momentum — here’s how many Americans support them
July 28, 2021MarketWatch
COVID-19 vaccine mandates gain momentum — here’s how many Americans support them
Opinion: Here’s your to-do list before the stock market’s next dive
July 27, 2021MarketWatch
Opinion: Here’s your to-do list before the stock market’s next dive
3 Top Robinhood Stocks to Buy in August Instead of Dogecoin
August 01, 2021The Motley Fool
3 Top Robinhood Stocks to Buy in August Instead of Dogecoin
FB whistleblower on Big Tech, Section 230 and the fight against bot networks
July 31, 2021FOX Business
FB whistleblower on Big Tech, Section 230 and the fight against bot networks
Opinion: Smart stock investors know to check this telling sign of a company’s health
July 29, 2021MarketWatch
Opinion: Smart stock investors know to check this telling sign of a company’s health
Which ETFs will Robinhood’s buzzy stock find itself in and when?
July 29, 2021MarketWatch
Which ETFs will Robinhood’s buzzy stock find itself in and when?
Why buying a condo for your college kid could be a smart financial move
July 28, 2021MarketWatch
Why buying a condo for your college kid could be a smart financial move
Opinion: You can beat stock market indexes — this fund manager has, and this is how she and her team did it
July 28, 2021MarketWatch
Opinion: You can beat stock market indexes — this fund manager has, and this is how she and her team did it
Are teachers next in line for vaccine mandates? ‘It’s going be a very difficult school year’
July 28, 2021MarketWatch
Are teachers next in line for vaccine mandates? ‘It’s going be a very difficult school year’
The labor shortage is worse than it looks, and help is not on the way
July 30, 2021MarketWatch
The labor shortage is worse than it looks, and help is not on the way
One government program cut poverty more than any other this year — and it’s ‘extremely unlikely’ to return any time soon
July 29, 2021MarketWatch
One government program cut poverty more than any other this year — and it’s ‘extremely unlikely’ to return any time soon
U.S. stocks fall Friday, booking weekly losses, but S&P 500 index up for 6 straight months
July 30, 2021MarketWatch
U.S. stocks fall Friday, booking weekly losses, but S&P 500 index up for 6 straight months
Here are the events likely to move financial markets in the coming days
July 28, 2021FOX Business
Here are the events likely to move financial markets in the coming days